Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VDAC1P12 refers to a pseudogene of the voltage-dependent anion channel 1 gene (VDAC1). The canonical/functional form, VDAC1, encodes a mitochondrial outer membrane protein important in metabolite transport, energy metabolism, apoptosis, and is implicated in tumorigenesis and cancer therapy development[1][2]. However, VDAC1P12 is not a protein-coding gene but a pseudogene—meaning it is a genomic remnant with high sequence similarity to VDAC1 but lacking the ability to produce a functional protein product. Pseudogenes do not encode active targets, are not enzymes, receptors, channels, or transporters, and thus are not considered therapeutic targets. There are no aliases in use other than referencing it as a pseudogene. There is nothing in the literature suggesting VDAC1P12 has biological function, disease association, or utility in drug development, biomarker assessment, or clinical targeting. If your intent was an active drug target, the correct entry is Voltage-dependent anion channel 1 (VDAC1). VDAC1P12, as a pseudogene, should not be considered a druggable target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent anion channel 1 pseudogene 12 (VDAC1P12).